| pubmed-article:2495916 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2495916 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:2495916 | lifeskim:mentions | umls-concept:C0011860 | lld:lifeskim |
| pubmed-article:2495916 | lifeskim:mentions | umls-concept:C0021641 | lld:lifeskim |
| pubmed-article:2495916 | lifeskim:mentions | umls-concept:C0015827 | lld:lifeskim |
| pubmed-article:2495916 | lifeskim:mentions | umls-concept:C0441472 | lld:lifeskim |
| pubmed-article:2495916 | lifeskim:mentions | umls-concept:C0442805 | lld:lifeskim |
| pubmed-article:2495916 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:2495916 | pubmed:dateCreated | 1989-6-7 | lld:pubmed |
| pubmed-article:2495916 | pubmed:abstractText | These studies examined the effect of fenfluramine on insulin action and insulin secretion in healthy subjects and patients with non-insulin-dependent diabetes mellitus (NIDDM). In the first study, a double-blind crossover design was used in healthy subjects to compare the effect of short-term fenfluramine therapy (60 mg orally for 3 days) with placebo. Insulin secretion and whole-body insulin sensitivity (determined by frequently sampled intravenous glucose tolerance tests with analysis by the minimal-model method) were unchanged by fenfluramine. In the second study, involving patients with NIDDM inadequately controlled on submaximal to maximal doses of oral hypoglycemic agents, a double-blind crossover strategy was used to compare baseline studies (conducted after a run-in period) with fenfluramine (60 mg orally) or placebo for 4 wk. There was a significant fall in fasting blood glucose after therapy with fenfluramine compared with the baseline study period (13.0 +/- 1.2 vs. 8.4 +/- 0.89 mM, mean +/- SE, P less than .01) with no significant fall in fasting serum insulin (20 +/- 2 vs. 24 +/- 3 microU/ml) or C-peptide (1.3 +/- 0.2 vs. 1.3 +/- 0.1 nM). During euglycemic-hyperinsulinemic (1 mU.kg-1.min-1) clamp studies there was a significant increase in insulin action from 12.7 +/- 2.3 to 17.3 +/- 1.8 min-1.10(3) microU.ml-1 (P less than .05), although clamp insulin levels were lower after fenfluramine treatment (136 +/- 14 vs. 96 +/- 9 microU/ml, P less than .02), reflecting an enhanced metabolic clearance rate for insulin (12.7 +/- 1.5 vs. 20.1 +/- 2.1 ml.kg-1.min-1, P less than .025).(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:2495916 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2495916 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2495916 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2495916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2495916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2495916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2495916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2495916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2495916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2495916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2495916 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2495916 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:2495916 | pubmed:issn | 0149-5992 | lld:pubmed |
| pubmed-article:2495916 | pubmed:author | pubmed-author:WardG MGM | lld:pubmed |
| pubmed-article:2495916 | pubmed:author | pubmed-author:AlfordF PFP | lld:pubmed |
| pubmed-article:2495916 | pubmed:author | pubmed-author:BestJ DJD | lld:pubmed |
| pubmed-article:2495916 | pubmed:author | pubmed-author:CrockP APA | lld:pubmed |
| pubmed-article:2495916 | pubmed:author | pubmed-author:PestellR GRG | lld:pubmed |
| pubmed-article:2495916 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2495916 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:2495916 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2495916 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2495916 | pubmed:pagination | 252-8 | lld:pubmed |
| pubmed-article:2495916 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:2495916 | pubmed:meshHeading | pubmed-meshheading:2495916-... | lld:pubmed |
| pubmed-article:2495916 | pubmed:meshHeading | pubmed-meshheading:2495916-... | lld:pubmed |
| pubmed-article:2495916 | pubmed:meshHeading | pubmed-meshheading:2495916-... | lld:pubmed |
| pubmed-article:2495916 | pubmed:meshHeading | pubmed-meshheading:2495916-... | lld:pubmed |
| pubmed-article:2495916 | pubmed:meshHeading | pubmed-meshheading:2495916-... | lld:pubmed |
| pubmed-article:2495916 | pubmed:meshHeading | pubmed-meshheading:2495916-... | lld:pubmed |
| pubmed-article:2495916 | pubmed:meshHeading | pubmed-meshheading:2495916-... | lld:pubmed |
| pubmed-article:2495916 | pubmed:meshHeading | pubmed-meshheading:2495916-... | lld:pubmed |
| pubmed-article:2495916 | pubmed:meshHeading | pubmed-meshheading:2495916-... | lld:pubmed |
| pubmed-article:2495916 | pubmed:meshHeading | pubmed-meshheading:2495916-... | lld:pubmed |
| pubmed-article:2495916 | pubmed:meshHeading | pubmed-meshheading:2495916-... | lld:pubmed |
| pubmed-article:2495916 | pubmed:meshHeading | pubmed-meshheading:2495916-... | lld:pubmed |
| pubmed-article:2495916 | pubmed:meshHeading | pubmed-meshheading:2495916-... | lld:pubmed |
| pubmed-article:2495916 | pubmed:meshHeading | pubmed-meshheading:2495916-... | lld:pubmed |
| pubmed-article:2495916 | pubmed:meshHeading | pubmed-meshheading:2495916-... | lld:pubmed |
| pubmed-article:2495916 | pubmed:meshHeading | pubmed-meshheading:2495916-... | lld:pubmed |
| pubmed-article:2495916 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2495916 | pubmed:articleTitle | Fenfluramine increases insulin action in patients with NIDDM. | lld:pubmed |
| pubmed-article:2495916 | pubmed:affiliation | University of Melbourne, Department of Medicine, St. Vincent's Hospital, Victoria, Australia. | lld:pubmed |
| pubmed-article:2495916 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2495916 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2495916 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:2495916 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:2495916 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2495916 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2495916 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2495916 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2495916 | lld:pubmed |
